HCW Biologics to present clinical development, IP program update

HCW Biologics will participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City. On September 12, 2023, the Company will be meeting individual investors in person at the conference venue, the Lotte New York Palace Hotel in New York. In addition, a pre-recorded, virtual Company update will be available on demand beginning at 7:00 a.m. EDT on September 11, 2023 for all who register for the conference. The update on clinical development will include a Phase 1 clinical trial to evaluate HCW9218 in solid tumors, sponsored by The Masonic Cancer Center, University of Minnesota. UMN is now dosing patients at the highest dose level. Due to clinical protocol requirements, dosing of the remaining patients is expected to take place in the next 3 to 6 months. The trial participants include patients with refractory/chemo-resistant ovarian cancer and colorectal cancer. There has been no dose-limiting toxicity observed in this study. In a second ongoing clinical study, a Company-sponsored Phase 1b/2 clinical trial to evaluate HCW9218 in advanced pancreatic cancer, the Company expects this study to be completed in the first half of 2024. There has been no dose-limiting toxicity observed in this study. This is a multi-center trial, led by the Center for Cancer Research at the National Cancer Institute. Dr. Christine Camp Alewine, M.D., Ph.D., is the principal investigator for the NCI clinical site. She is a Lasker Clinical Research Scholar in the Laboratory of Molecular Biology at the Center for Cancer Research at NCI and a foremost expert in pancreatic cancer research.